title: Effect of nedocromil on antigen-induced bronchoconstriction in asthmatic subjects.
abstract: Nedocromil sodium, a pyranoquinoline decarboxylic acid derivative, is a new antiasthma compound undergoing clinical investigation. It has been shown to be effective in the management of asthma and to attenuate exercise-induced bronchoconstriction. We performed a randomized, double-blind, placebo-controlled, crossover study in 12 ragweed-sensitive subjects known to respond to inhaled ragweed antigen. On two study days, four to ten days apart, ragweed challenges were performed using a standard protocol 30 minutes after a single dose (two puffs of 2 mg/puff) of either active drug or placebo. The PD20 (20% fall in FEV1) for each treatment day was compared by parametric and nonparametric 2-period crossover analyses. Baseline FEV1 pre-drug and post-drug administration did not differ significantly between study days. On the nedocromil day, the mean +/- SD for log PD20 was 2.25 +/- 0.561 and on the placebo day, 1.73 +/- 1.048 (P = 0.04). There were no side effects associated with either treatment. These results demonstrate that nedocromil is effective in shifting the stimulus response curve to inhaled antigen in some ragweed-sensitive subjects. Its wide spectrum of efficacy against bronchoprovocation suggests it is useful in the treatment of hyperreactive airway disorders.
authors.affiliation: Allergic Disease Center, Creighton University, Omaha, Nebraska.
authors.forename: N
authors.initials: N
authors.lastname: Nair
authors.forename: R J
authors.initials: RJ
authors.lastname: Hopp
authors.forename: R
authors.initials: R
authors.lastname: Townley
mesh_terms: D000280:Administration, Inhalation; D000328:Adult; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D000941:Antigens / Q000008:administration & dosage / Q000494:pharmacology*; D001249:Asthma / Q000188:drug therapy; D001980:Bronchi / Q000187:drug effects* / Q000473:pathology; D001985:Bronchial Provocation Tests; D003251:Constriction, Pathologic / Q000188:drug therapy / Q000209:etiology; D005541:Forced Expiratory Volume; D006801:Humans; D008297:Male; D008875:Middle Aged; D017835:Nedocromil; D015363:Quinolones / Q000627:therapeutic use*; D013997:Time Factors
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D000941:Antigens; D015363:Quinolones; D017835:Nedocromil